A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

PHASE3CompletedINTERVENTIONAL
Enrollment

475

Participants

Timeline

Start Date

August 30, 2019

Primary Completion Date

December 22, 2020

Study Completion Date

January 13, 2021

Conditions
Type 2 Diabetes
Interventions
DRUG

Tirzepatide

Administered SC as add-on to the pre-trial background medication.

DRUG

Placebo

Administered SC as add-on to the pre-trial background medication.

Trial Locations (48)

10016

Manhattan Medical Research, New York

11000

Lekarna Dr. Max, Prague

14612

Praxis Dr. Jörg Lüdemann, Falkensee

21073

Diabetologische Schwerpunktpraxis B. Scholz/Dr. B. Paschen, Hamburg

22607

Gemeinschaftspraxis für innere Medizin und Diabetologie, Hamburg

23758

RED-Institut GmbH, Oldenburg in Holstein

25001

Diacentrum Brandys n.L. s.r.o., Brandys Nad Labem-Stara Bolesl

26201

Milan Kvapil s.r.o., Příbram

29010

Hospital Clinico Universitario Virgen de la Victoria, Málaga

34652

Sun Coast Clinical Research, Inc, New Port Richey

35415

Arztpraxis Dr. Cornelia Marck, Pohlheim

39112

SMO.MD GmbH, Magdeburg

41009

Hospital Universitario Virgen Macarena, Seville

41010

Hospital Infanta Luisa, Seville

45136

InnoDiab Forschung GmbH, Essen

46026

Hospital Universitari i Politecnic La Fe-ENDO, Valencia

46600

Hospital de la Ribera, Alzira

48145

Institut für Diabetesforschung Münster GmbH, Münster

53002

Diahelp s.r.o., Interni a diabetologicka ambulance, Pardubice

66386

Schwerpunktpraxis Diabetes, Saint Ingbert-Oberwürzbach

67059

Praxis Dr. Kempe - Dr. Stemler, Ludwigshafen am Rhein

73069

Intend Research, Norman

79401

Diabetologicka ordinace pro dospele, Krnov

93720

Valley Endocrine, Fresno, Fresno

98101

Ambulancia vnútorného lekárstva Hnúša (Diabetes care), Hnúšťa

1030002

The Institute for Adult Diseases, Asahi Life Foundation, Chuou-ku

03063

Southern New Hampshire Diabetes and Endocrinology, Nashua

149 00

Milan Kvapil s.r.o., Prague

181 00

RESTRIAL s.r.o., Prague

277-0825

Kashiwa hospital, Kashiwa

060-0062

Manda Hospital, Sapporo

247-0056

Takai Naika Clinic, Kamakura

569-1096

Takatsuki Red Cross Hospital, Takatsuki

103-0027

Tokyo-Eki Center-building Clinic, Chuo-ku

103-0028

Tokyo Center Clinic, Chuo-ku

104-0031

Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku

143-0015

Sato Naika Clinic, Ōta-ku

862-0976

Jinnouchi Hospital, Kumamoto

01-518

Centrum Medyczne AMED, Warsaw

15-351

NZOZ ZDROWIE Osteo-Medic, Bialystok

80-546

Centrum Badan Klinicznych, PI House, Gdansk

20-538

NZOZ Przychodnia Specjalistyczna MEDICA, Lublin

00725

Centro de Endocrinologia y Nutricion del Turabo, Caguas

00674

Manati Center for Clinical Research Inc, Manatí

901 01

Sin Azucar, Malacky

971 01

Dia-Clarus.s.r.o., Prievidza

917 01

JAL, Trnava

01001

Medivasa, s.r.o., Žilina

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04039503 - A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin | Biotech Hunter | Biotech Hunter